Analyzing RNDO-564 Efficacy with Cell Line & Syngenic Mouse Model to Deliver Robust Anti-Tumor Responses
9:00 am - Thursday 29th January 2026
- Harnessing affinity-tuned CD28 costimulation with high-affinity Nectin-4 targeting to maximize localized T-cell activation and potentiate anti-tumor cytotoxicity
- Demonstrating strong in vitro activity through enhanced cytotoxicity and cytokine release against Nectin-4–positive tumor cell lines under signal 1 conditions
- Achieving dose-dependent tumor growth inhibition in syngeneic models and favorable tolerability in primates to validate translational therapeutic potential
